UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On March 11, 2021, Lineage Cell Therapeutics, Inc. issued a press release announcing financial results for the quarter and year ended December 31, 2020, a copy of which is furnished as Exhibit 99.1.
The information under this Item 2.02 and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press release issued March 11, 2021 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Lineage Cell Therapeutics, Inc. | ||
| Date: March 11, 2021 | By: | /s/ Brian M. Culley |
| Name: | Brian M. Culley | |
| Title: | Chief Executive Officer | |
Exhibit 99.1
LINEAGE CELL THERAPEUTICS REPORTs FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
| ● | Completed Enrollment in Phase 1/2a Clinical Trial of OpRegen for the Treatment of Dry Age-Related Macular Degeneration | |
| ● | Announced First Known Report of Human Retinal Tissue Restoration; Persisted to 23 Months with Improved Vision | |
| ● | Made Significant Improvements to OPC1 Manufacturing, Including to Process, Purity, and Scale | |
| ● | Reacquired the VAC Immuno-Oncology Platform and Reported Initial Data in Ongoing Phase 1 Clinical Trial in Non-Small Cell Lung Cancer | |
| ● | Received $24.6 Million Installment Payment from Juvenescence Ltd. Related to Sale of AgeX Therapeutics | |
| ● | Current Cash Position Expected to Support Operations Well Into 2023 |
CARLSBAD, CA – March 11, 2021 - Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the fourth quarter and full year 2020. Lineage management will host a conference call and webcast today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2020 financial and operating results and to provide a business update.
“Our goal is to build Lineage into the preeminent allogeneic cell transplant company, and we hit our stride in 2020, reaching significant clinical, manufacturing, and business milestones and creating substantial value for our shareholders. We also positioned ourselves for success in 2021 and beyond,” stated Brian M. Culley, Lineage CEO. “We know of no other company that possesses a comparable combination of cell therapy patent breadth, in-house manufacturing capabilities, and encouraging clinical evidence in three distinct disease areas, each with large unmet needs and billion-dollar commercial opportunities. We believe the field of cell therapy is poised for explosive growth in the months and years ahead. Our objective is to be positioned for that growth by continuing to provide evidence that allogeneic approaches can generate safety and efficacy data which leads to commercial and clinical advantages over alternate approaches. Importantly, Lineage also recently added $35.9 million in new capital through the timely sales of our equity and marketable securities. We believe this new capital will ensure we are funded to deliver additional significant milestones from our novel cell therapy pipeline and provide us with optionality in ongoing partnership discussions.”
Some of the significant milestones we achieved during 2020 include:
| - | Completion of enrollment in a 24 patient Phase 1/2a clinical study of OpRegen® for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA) with encouraging preliminary signs of tolerability and efficacy; |
| - | Announcing the first known finding of retinal tissue restoration in a patient who received a retinal pigment epithelium (RPE) cell transplant which had persisted to 23 months with further improvements to visual acuity; |
| - | Making major manufacturing improvements to our OPC1 acute spinal cord injury (SCI) program, including to the process, purity, and scale, and to the development of a “ready-to-inject” formulation, enabling use at a much larger number of treatment centers; |
| - | The early exercise of our option with Cancer Research UK to bring the VAC immuno-oncology platform in-house; |
| - | Reporting encouraging preliminary Phase 1 clinical study results with VAC2 for the treatment of non-small cell lung cancer with evidence of high levels of antigen-specific immunogenicity observed in all patients treated to date; |
| - | Receiving a new research & development grant from the Israel Innovation Authority under their bio-convergence initiative, for the development of a novel bio-retinal patch for the treatment of retinal diseases in partnership with Precise Bio Ltd.; |
| - | Announcing the extension of an OpRegen development grant from the Israel Innovation Authority; |
| - | Receiving a $24.6 million payment from Juvenescence Ltd. for principal and interest due under a convertible promissory note issued as partial payment for the sale of common stock of AgeX Therapeutics, Inc.; and |
| - | Successfully monetizing portions of Lineage’s non-core patent portfolio. |
Some of the events and milestones that our shareholders can look forward to in 2021 include:
| - | Present new and accumulated OpRegen data from the ongoing Phase 1/2a clinical study on two occasions during the first and second quarters of 2021; |
| - | Plan to meet with the FDA to discuss further clinical development of the OpRegen program, anticipated in the third quarter of 2021; |
| - | Complete VAC2 patient enrollment in the ongoing Phase 1 clinical study for the treatment of non-small cell lung cancer, anticipated in the second quarter of 2021; |
| - | Evaluate the Neurgain Parenchymal Spinal Delivery (PSD) system for OPC1, currently ongoing and throughout 2021; |
| - | Plan to meet with the FDA to discuss plans to evaluate the Neurgain Parenchymal Spinal Delivery (PSD) system for OPC1, anticipated in the second quarter of 2021; |
| - | Complete OPC1 process development to support a late-stage clinical trial, currently ongoing and throughout 2021; |
| - | Introduce manufacturing enhancements to the VAC2 program, anticipated throughout 2021; |
| - | Report results from the ongoing Phase 1 clinical study of VAC2 for the treatment of non-small cell lung cancer, anticipated in the fourth quarter of 2021; |
| - | Plan to meet with the FDA to discuss further development of the OPC1 program and manufacturing improvements, including a late-stage clinical study, anticipated in the fourth quarter of 2021; |
| - | Evaluate opportunities for new VAC product candidates based on newly discovered tumor antigens/neoantigens, throughout 2021; and |
| - | Evaluate partnership opportunities and expansion of existing external collaborations and identification of new collaborations for OpRegen, OPC1 and VAC2, currently ongoing and throughout 2021. |
Balance Sheet Highlights
Cash, cash equivalents, and marketable securities totaled $41.6 million as of December 31, 2020. Marketable securities as of December 31, 2020 include our remaining ownership of unrestricted securities in OncoCyte, and Hadasit Bio-Holdings Ltd (Hadasit).
During 2020, we funded our operations primarily by receiving payment in full for a total of $24.6 million on the Juvenescence promissory note, and by selling a portion of our marketable securities, resulting in net proceeds of approximately $13.1 million.
Additionally, during 2020, we selectively sold 3,094,322 of our common shares under the ATM offering for gross proceeds of approximately $5.1 million (which excludes $0.3 million of cash in transit related to 2020 sales that settled in 2021).
| Page 2 |
2021 fundraising activities
From January 1, 2021 through March 5, 2021, we sold an additional portion of our marketable securities, resulting in net proceeds of approximately $10.1 million and an additional $19.9 million in gross proceeds through sales of 7,941,122 of our common shares under the ATM offering (which includes $0.3 million in cash in transit related to 2020 sales that settled in 2021). As of March 5, 2021, the value of the Company’s cash and cash equivalents were in excess of $57 million.
As of March 5, 2021, we hold 1,122,401 shares of OncoCyte stock valued at approximately $4.2 million and 169,167 shares of Hadasit stock valued at approximately $330,000, in each case based on the closing prices of those shares on March 5, 2021.
The Company anticipates that net operational spend for 2021 will be approximately $20.0 to $22.0 million, which is similar to 2020 spending levels. The Company believes that it is well funded into 2023 as a result of sustained cost savings initiatives in 2020 and recent fundraising activities.
Fourth Quarter Operating Results
Revenues: Lineage’s revenue is generated primarily from research grants, royalties, and licensing fees. Total revenues for the three months ended December 31, 2020 were approximately $0.4 million, a decrease of $0.8 million as compared to $1.2 million for the same period in 2019. The decrease was primarily related to an approximate $0.6 million decrease in royalties and licensing fees, which was primarily driven by the absence of a $0.6 million upfront payment from a new license agreement in 2019, and a $0.2 million decrease in grant revenues due to the timing of grant related activities.
Operating Expenses: Operating expenses are comprised of research and development (R&D) expenses and general and administrative (G&A) expenses. Total operating expenses for the three months ended December 31, 2020 were $6.1 million, a decrease of $1.9 million as compared to $8.0 million for the same period in 2019.
R&D Expenses: R&D expenses for the three months ended December 31, 2020 were $2.6 million, a decrease of $0.9 million as compared to $3.5 million for the same period in 2019. The overall decrease was primarily related to decreases of $1.5 million in OpRegen and other ophthalmic application expenses, attributable primarily to a decrease in manufacturing activities in 2020 as compared to 2019, and $0.1 million in Renevia and HyStem related expenses, offset by an increase of $0.5 million in OPC1 expenses, attributable primarily to an increase in manufacturing activities, and a $0.3 million increase in VAC program expenses.
G&A Expenses: G&A expenses for the three months ended December 31, 2020 were $3.5 million, a decrease of $1.0 million as compared to $4.5 million for the same period in 2019. The decrease was primarily attributable to decreases of $0.4 million in legal and patent expenses, $0.3 million in rent expense, $0.3 million in expenses related to our merger with Asterias Biotherapeutics, Inc. (Asterias Merger) and $0.2 million in accounting and consulting expenses, offset by a $0.2 million increase related to the cessation of shared services reimbursements.
Loss from Operations: Loss from operations for the three months ended December 31, 2020 was $5.9 million, a decrease of $1.0 million as compared to $6.9 million for the same period in 2019.
Other Income/(Expenses), Net: Other income/(expenses), net for the three months ended December 31, 2020 reflected other income, net of $6.9 million, compared to other income, net of $1.5 million for the same period in 2019. The variance was primarily related to the gain on sale of marketable securities and changes in the value of marketable equity securities for the applicable periods, as well as foreign currency translation adjustments related to Lineage’s international subsidiaries.
Net Income/(Loss) attributable to Lineage: The net income attributable to Lineage for the three months ended December 31, 2020 was $2.0 million, or $0.01 per share (basic and diluted), compared to a net loss attributable to Lineage of ($4.5) million, or ($0.03) per share (basic and diluted), for the same period in 2019.
| Page 3 |
Full Year Operating Results
Revenues: Lineage’s revenue is generated primarily from research grants, royalties, and licensing fees. Total revenues for the year ended December 31, 2020 were $1.8 million, a decrease of $1.7 million as compared to $3.5 million for the same period in 2019. The decrease was primarily related to a $1.0 million decrease in grant revenue due to less grant-related activities, $0.4 million decrease in royalties from product sales and license fees, and a $0.3 million decrease in the sale of research products and services due to the cessation of such sales.
Operating Expenses: Operating expenses are comprised of R&D expenses and G&A expenses. Total operating expenses for the year ended December 31, 2020 were $27.9 million, a decrease of $14.1 million as compared to $42.0 million for the same period in 2019.
R&D Expenses: R&D expenses for the year ended December 31, 2020 were $12.3 million, a decrease of $5.6 million as compared to $17.9 million for the same period in 2019. The overall decrease was primarily related to a decrease of $6.5 million in OpRegen and other ophthalmic application expenses, attributable primarily to a decrease in manufacturing activities in 2020 as compared to 2019, a decrease of $0.8 million in Renevia and other related expense as we are spending less and actively looking for a commercialization partner, and a $0.5 million decrease in OPC1-related expenses, primarily driven by a return of unspent project funds of approximately $0.8 million from a former Asterias service provider, offset by a $2.2 million increase in VAC program expenses, primarily related to the accrual of the signature fee of £1.25 million ($1.6 million) to Cancer Research UK.
G&A Expenses: G&A expenses for the year ended December 31, 2020 were $15.6 million, a decrease of approximately $8.4 million as compared to $24.0 million for the same period in 2019. The decrease was primarily attributable to a $5.5 million decrease in Asterias Merger related expenses, a $2.1 million reduction in compensation costs as a result of headcount reductions in 2019, a $0.9 million reduction in accounting expenses, a $0.5 million reduction in rent and utilities, a $0.3 million reduction in travel expenses, a $0.3 million reduction in office and information technology related expenses and a $0.2 million reduction in consulting expenses, offset by a $0.9 million increase related to the cessation of shared services reimbursements and a $0.5 million increase in legal and patent expenses.
Loss from Operations: Loss from operations for the year ended December 31, 2020 was $26.4 million, a decrease of $12.5 million as compared to $38.9 million for the same period in 2019.
Other Income, Net: Other income, net for the year ended December 31, 2020 reflected other income, net of $4.5 million, compared to other income, net of $19.6 million for the same period in 2019. The variance was primarily related to the changes in the value of equity method investments and marketable equity securities for the applicable periods, gain on sale of marketable securities for the applicable periods, as well as foreign currency translation adjustments related to Lineage’s international subsidiaries.
Net loss attributable to Lineage: The net loss attributable to Lineage for the year ended December 31, 2020 was $20.6 million, or $0.14 per share (basic and diluted), compared to a net loss attributable to Lineage of $11.7 million, or $0.08 per share (basic and diluted), for 2019.
Conference Call and Webcast
Lineage will host a conference call and webcast today, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2020 financial results and to provide a business update. Interested parties may access the conference call by dialing (866) 888-8633 from the U.S. and Canada and (636) 812-6629 from elsewhere outside the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”. A live webcast of the conference call will be available online in the Investors section of Lineage’s website. A replay of the webcast will be available on Lineage’s website for 30 days and a telephone replay will be available through March 19, 2021, by dialing (855) 859-2056 from the U.S. and Canada and (404) 537-3406 from elsewhere outside the U.S. and Canada and entering conference ID number 4176568.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.
| Page 4 |
Forward-Looking Statements
Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to Lineage’s anticipated net operational spend for 2021, data presentations, clinical trial advancement, planned meetings with the FDA and partnership evaluations. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineage’s business and other risks in Lineage’s filings with the Securities and Exchange Commission (the SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the SEC, including Lineage’s most recent Annual Report on Form 10-K filed with the SEC and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(ir@lineagecell.com)
(442) 287-8963
Solebury Trout IR
Gitanjali Jain Ogawa
(Gogawa@troutgroup.com)
(646) 378-2949
Russo Partners – Media Relations
Nic Johnson or David Schull
Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com
(212) 845-4242
Tables to follow
| Page 5 |
LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)
| December 31, 2020 | December 31, 2019 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS | ||||||||
| Cash and cash equivalents | $ | 32,585 | $ | 9,497 | ||||
| Marketable equity securities | 8,977 | 21,219 | ||||||
| Promissory note from Juvenescence | - | 23,616 | ||||||
| Trade accounts and grants receivable, net | 4 | 317 | ||||||
| Receivables from affiliates, net | - | 7 | ||||||
| Prepaid expenses and other current assets | 2,433 | 2,863 | ||||||
| Total current assets | 43,999 | 57,519 | ||||||
| NONCURRENT ASSETS | ||||||||
| Property and equipment, net | 5,630 | 8,175 | ||||||
| Deposits and other long-term assets | 616 | 864 | ||||||
| Goodwill | 10,672 | 10,672 | ||||||
| Intangible assets, net | 47,032 | 48,248 | ||||||
| TOTAL ASSETS | $ | 107,949 | $ | 125,478 | ||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| CURRENT LIABILITIES | ||||||||
| Accounts payable and accrued liabilities | $ | 6,813 | $ | 5,226 | ||||
| Financing lease and right-of-use liabilities, current portion | 762 | 1,223 | ||||||
| Deferred revenues | 193 | 45 | ||||||
| Liability classified warrants, current portion | 1 | - | ||||||
| Total current liabilities | 7,769 | 6,494 | ||||||
| LONG-TERM LIABILITIES | ||||||||
| Deferred tax liability | 2,076 | 3,315 | ||||||
| Deferred revenues, net of current portion | - | 200 | ||||||
| Right-of-use lease liability, net of current portion | 2,514 | 3,868 | ||||||
| Financing lease, net of current portion | 26 | 77 | ||||||
| Liability classified warrants and other long-term liabilities | 437 | 277 | ||||||
| TOTAL LIABILITIES | 12,822 | 14,231 | ||||||
| Commitments and contingencies | ||||||||
| SHAREHOLDERS’ EQUITY | ||||||||
| Preferred shares, no par value, authorized 2,000 shares; none issued and outstanding as of December 31, 2020 and 2019, respectively | - | - | ||||||
| Common shares, no par value, authorized 250,000 shares; 153,096 and 149,804 shares issued and outstanding as of December 31, 2020 and 2019, respectively | 393,944 | 387,062 | ||||||
| Accumulated other comprehensive loss | (3,667 | ) | (681 | ) | ||||
| Accumulated deficit | (294,078 | ) | (273,422 | ) | ||||
| Lineage Cell Therapeutics, Inc. shareholders’ equity | 96,199 | 112,959 | ||||||
| Noncontrolling interest (deficit) | (1,072 | ) | (1,712 | ) | ||||
| Total shareholders’ equity | 95,127 | 111,247 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 107,949 | $ | 125,478 | ||||
| Page 6 |
LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
| Year Ended December 31, | ||||||||
| 2020 | 2019 | |||||||
| REVENUES: | ||||||||
| Grant revenue | $ | 1,053 | $ | 2,037 | ||||
| Royalties from product sales and license fees | 773 | 1,221 | ||||||
| Sale of research products and services | - | 257 | ||||||
| Total revenues | 1,826 | 3,515 | ||||||
| Cost of sales | (385 | ) | (412 | ) | ||||
| Gross profit | 1,441 | 3,103 | ||||||
| OPERATING EXPENSES: | ||||||||
| Research and development | 12,317 | 17,948 | ||||||
| General and administrative | 15,571 | 24,031 | ||||||
| Total operating expenses | 27,888 | 41,979 | ||||||
| Loss from operations | (26,447 | ) | (38,876 | ) | ||||
| OTHER INCOME, NET: | ||||||||
| Interest income, net | 1,039 | 1,685 | ||||||
| Gain on sale of marketable securities | 4,560 | 2,421 | ||||||
| Gain on sale of equity method investment in OncoCyte | - | 546 | ||||||
| Unrealized loss on marketable equity securities | (3,782 | ) | (2,898 | ) | ||||
| Unrealized gain on equity method investment in OncoCyte at fair value | - | 8,001 | ||||||
| Unrealized gain on equity method investment in Asterias at fair value | - | 6,744 | ||||||
| Unrealized (loss) gain on warrant liability | (174 | ) | 611 | |||||
| Other income, net | 2,880 | 2,532 | ||||||
| Total other income, net | 4,523 | 19,642 | ||||||
| LOSS BEFORE INCOME TAXES | (21,924 | ) | (19,234 | ) | ||||
| Income tax benefit | 1,239 | 7,407 | ||||||
| NET LOSS | (20,685 | ) | (11,827 | ) | ||||
| Net loss attributable to noncontrolling interest | 36 | 118 | ||||||
| NET LOSS ATTRIBUTABLE TO LINEAGE | $ | (20,649 | ) | $ | (11,709 | ) | ||
| NET LOSS PER COMMON SHARE: | ||||||||
| BASIC AND DILUTED | $ | (0.14 | ) | $ | (0.08 | ) | ||
| WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: | ||||||||
| BASIC AND DILUTED | 150,044 | 145,533 | ||||||
| Page 7 |
LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
| Year Ended December 31, | ||||||||
| 2020 | 2019 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss attributable to Lineage | $ | (20,649 | ) | $ | (11,709 | ) | ||
| Net loss attributable to noncontrolling interest | (36 | ) | (118 | ) | ||||
| Adjustments to reconcile net loss attributable to Lineage to net cash used in operating activities: | ||||||||
| Unrealized gain on equity method investment in OncoCyte at fair value | - | (8,001 | ) | |||||
| Unrealized gain on equity method investment in Asterias at fair value | - | (6,744 | ) | |||||
| Gain on sale of marketable equity securities | (4,560 | ) | (2,967 | ) | ||||
| Unrealized loss on marketable equity securities | 3,782 | 2,898 | ||||||
| Income tax benefit | (1,239 | ) | (7,407 | ) | ||||
| Depreciation expense, including amortization of leasehold improvements | 823 | 1,002 | ||||||
| Amortization of right-of-use assets | 72 | 129 | ||||||
| Amortization of intangible assets | 1,216 | 1,998 | ||||||
| Stock-based compensation | 2,227 | 3,580 | ||||||
| Common stock issued for services | 119 | - | ||||||
| Change in unrealized loss (gain) on warrant liability | 174 | (611 | ) | |||||
| Write-off of security deposit | 150 | - | ||||||
| Amortization of deferred license fee | (200 | ) | - | |||||
| Foreign currency remeasurement and other (gain) loss | (2,957 | ) | (2,367 | ) | ||||
| (Gain) loss on sale of assets | (20 | ) | 273 | |||||
| Realized loss on warrant exercise | 44 | - | ||||||
| Dividend received | - | 182 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts and grants receivable, net | 287 | 467 | ||||||
| Accrued interest receivable | (1,008 | ) | (1,512 | ) | ||||
| Receivables from affiliates, net of payables | 7 | 2,105 | ||||||
| Prepaid expenses and other current assets | 1,575 | (260 | ) | |||||
| Accounts payable and accrued liabilities | 308 | (2,885 | ) | |||||
| Deferred revenue and other liabilities | 132 | - | ||||||
| Net cash used in operating activities | (19,753 | ) | (31,947 | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Proceeds from sale of OncoCyte common shares | 10,941 | 10,738 | ||||||
| Proceeds from the sale of AgeX common shares | 1,290 | 1,734 | ||||||
| Proceeds from the sale of Hadasit common shares | 830 | 1,743 | ||||||
| Cash and cash equivalents acquired in the Asterias Merger | - | 3,117 | ||||||
| Purchase of property and equipment | (64 | ) | (440 | ) | ||||
| Proceeds from sale of assets | 23 | 82 | ||||||
| Security deposit paid and other | 18 | (17 | ) | |||||
| Net cash provided by investing activities | 13,038 | 16,957 | ||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from payment of Juvenescence promissory note | 24,624 | - | ||||||
| Common shares received and retired for employee taxes paid | (27 | ) | (110 | ) | ||||
| Proceeds from sale of subsidiary warrants | - | (40 | ) | |||||
| Proceeds from sale of common shares | 5,127 | 103 | ||||||
| Payments for offering costs | (356 | ) | - | |||||
| Repayment of financing lease liabilities | (26 | ) | (30 | ) | ||||
| Proceeds from Paycheck Protection Program (“PPP”) Loan (Note 8) | 523 | - | ||||||
| Reimbursement from landlord on tenant improvements | - | 764 | ||||||
| Repayment of principal portion of promissory notes | - | (70 | ) | |||||
| Net cash provided by financing activities | 29,865 | 617 | ||||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (63 | ) | 70 | |||||
| NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | 23,087 | (14,303 | ) | |||||
| At beginning of year | 10,096 | 24,399 | ||||||
| At end of year | $ | 33,183 | $ | 10,096 | ||||
| Page 8 |